Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRKR - Marker Therapeutics Inc


IEX Last Trade
3.6
0.100   2.778%

Share volume: 15,181
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.50
0.10
2.86%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
19%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-1.50%
1 Month
-25.57%
3 Months
-9.98%
6 Months
-1.10%
1 Year
-38.29%
2 Year
20.01%
Key data
Stock price
$3.60
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.40 - $6.80
52 WEEK CHANGE
-$0.34
MARKET CAP 
32.211 M
YIELD 
N/A
SHARES OUTSTANDING 
8.923 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,065
AVERAGE 30 VOLUME 
$27,395
Company detail
CEO: Peter Hoang
Region: US
Website: https://www.tapimmune.com/
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini

Recent news